Otherwise, analysis of the maturation state of Lin-/HLA-DR+ DCs, evaluated as the expression of CD83 molecule, showed that breast cancer patients had a significantly higher percentage of mature CD83+ DCs compared with control subjects (5.23±0.57 vs 3.00±0.75%; P=0.019). This evidence concerns the gene CD83 and breast carcinoma.